Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Non-Current Debt for 5 consecutive years, with $107.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt rose 331.15% year-over-year to $107.9 million, compared with a TTM value of $107.9 million through Dec 2025, up 331.15%, and an annual FY2025 reading of $107.9 million, up 331.15% over the prior year.
  • Non-Current Debt was $107.9 million for Q4 2025 at Heron Therapeutics, roughly flat from $107.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $107.9 million in Q4 2025 and bottomed at $24.0 million in Q3 2023.
  • Average Non-Current Debt over 3 years is $43.1 million, with a median of $24.8 million recorded in 2024.
  • Peak annual rise in Non-Current Debt hit 332.93% in 2025, while the deepest fall reached 3.13% in 2025.
  • Year by year, Non-Current Debt stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then soared by 331.15% to $107.9 million in 2025.
  • Business Quant data shows Non-Current Debt for HRTX at $107.9 million in Q4 2025, $107.5 million in Q3 2025, and $25.2 million in Q1 2025.